▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

XMFEBCapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

Man pointing at dollar sign GettyImages-473559372

Aug 3, 2017 by Todd Campbell

Why Wright Medical Group Shares Are Spiking Higher Today

A better-than-expected second-quarter earnings report is fueling investor optimism.

pills on money GettyImages-507799948

Aug 2, 2017 by Todd Campbell

3 Reasons the Best Is Yet to Come for Celgene

Label expansions, collaborations, and internally developed drugs could catapult Celgene's financials higher in the coming years.

Rising_Stock_Chart

Aug 2, 2017 by Todd Campbell

Why PharMerica Stock Is Soaring Today

The company is being acquired by KKR and Walgreens Boots Alliance.

man in front of mic GettyImages-112156291

Aug 2, 2017 by Todd Campbell

3 Biotech Stocks With Big News Coming

Flexion Therapeutics, Keryx, and Zogenix have market-moving news on deck that could cause shares to soar or plummet in the next few months.

businessman boxing GettyImages-496166842

Aug 1, 2017 by Todd Campbell

Merck's Keytruda Plays Catch-Up to Bristol-Myers' Opdivo

The two biopharma giants PD-1 inhibitors are facing off against each other in cancer indications that are worth billions of dollars in annual sales.

business man points at dollar signs GettyImages-494940062

Aug 1, 2017 by Todd Campbell

Here's Why the Best Is Yet to Come for Exact Sciences

The company has only begun tapping into the large, unmet need for better colon cancer screening.

offshore rigs GettyImages-515446082

Aug 1, 2017 by Todd Campbell, Dan Caplinger, and Matt DiLallo

3 Energy Stocks to Buy at the Bottom of the Cycle

Transocean, Dawson Geophysical, and Encana are intriguing stocks to buy on sale in the energy sector.

market crash getty-images-sinking-stock-chart-woes_large

Jul 31, 2017 by Todd Campbell

Why Clovis Oncology Tumbled 13.5% Today

News of a collaboration with Bristol-Myers Squibb dashed some of investor's hopes that Clovis Oncology could get acquired.

IF_healthcare

Jul 31, 2017 by Todd Campbell

3 Hot Healthcare Stocks Under $30

Small-cap stocks Novocure, Flexion Therapeutics, and Zogenix want to shake up healthcare, and investors are optimistic about their chances.

money tree growing in jars GettyImages-49170429

Jul 29, 2017 by Todd Campbell

Should You Withdraw Money From An IRA So That You Can Claim Social Security At 70?

Claiming Social Security at age 70 gets you the biggest check, but if you're forced to retire sooner than that, it may be better to claim before then to avoid drawing down your IRAs.

money jar growing a money plant GettyImages-505872010 (1)

Jul 29, 2017 by Todd Campbell, Dan Caplinger, and Demitri Kalogeropoulos

3 Dividend Stocks You Haven't Thought Of

One sells wearable electronic fitness devices, another is booming because there are more cars are on the road, and the third is a gardening company that's riding high on pro-pot legislation.

capitol building GettyImages-513391670

Jul 28, 2017 by Todd Campbell

McCain Pulls the Plug on Obamacare "Skinny Repeal" Without Replacement

A last-minute effort to repeal health insurance requirements and taxes was voted down when Senators Collins, Murkowski, and McCain voted against it on Thursday.

retired couple gettu

Jul 28, 2017 by Todd Campbell

Is Taking Social Security at Age 66 Wise?

If you're debating whether or not to claim Social Security at age 66, you need to understand your options.

market crashing through the floor GettyImages-612737000

Jul 28, 2017 by Todd Campbell

Why Mednax Tumbled 12% Today Despite Higher Sales

The provider of specialized health services grew its year-over-year revenue thanks to acquisitions, but its profits sank.

market crash GettyImages-499578669

Jul 27, 2017 by Todd Campbell

Mighty AstraZeneca Takes a Lickin' on Failed Mystic Trial

AstraZeneca's attempts to challenge competitors for dominance in treating non-small lung cancer were dashed today when data from a key trial came up short.

GettyImages-476562658

Jul 27, 2017 by Todd Campbell

Why Tetraphase Pharmaceuticals Fell 11.7% Today

The company announced a stock offering that will bolster its balance sheet but also dilute current investors.

market crash getty-images-sinking-stock-chart-woes_large

Jul 27, 2017 by Todd Campbell

Why Community Health Shares Are Crashing 15.6% Today

The hospital company issued preliminary second-quarter financial results that missed the mark.

GettyImages-473559372

Jul 26, 2017 by Todd Campbell

Exact Sciences Continues to Surprise to the Upside

Exact Sciences delivered yet another quarter of greater than 100% top-line growth.

frustrated-stock-traders-multiple-charts-forecasting-getty_large

Jul 26, 2017 by Todd Campbell

Why Amedisys Is Crashing 14.3% Today

Government reimbursement rates may slip 0.4% in 2018, and that's pressuring stocks across the home healthcare industry.

market crash GettyImages-499578669

Jul 25, 2017 by Todd Campbell

Why Pacira Pharmaceuticals Shares Are Crashing 15% Today

Disappointing late-stage trial data is dashing investor optimism.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services